Industry: Biotechnology
Article
Interacting with Members and Refining My Frameworks
Feb 22, 2022
Speaking with members has helped me to fine-tune my research process with clearer communication in mind.
By Maxx Chatsko
Video
Dana’s Top Stock for February 2022
Feb 1, 2022
7investing Lead Advisor Dana Abramovitz's top stock to buy in February 2022 is a biotechnology company that has its eyes set on an ambitious goal and is using a variety of approaches to avoid...
Biotechnology
Article
Wild Prediction for 2022: CRISPR Stocks Become Mortal Again
Jan 22, 2022
Emerging therapeutic modalities built on the enzymatic tool will be subject to the traditional risk-reward calculus facing drug developers.
By Maxx Chatsko
Premium Advisor Update
Should You Invest in Synthetic Biology Stocks?
Jan 14, 2022
By Maxx Chatsko
Video
Maxx’s Top Stock for January 2022
Jan 1, 2022
7investing Lead Advisor Maxx Chatsko's top stock to buy in January 2022 is developing a novel technology platform that's well-positioned to address some of the biggest challenges facing gene therapy...
By Maxx Chatsko
Article
Dicerna Pharmaceuticals Deep Dive: October 2021
Dec 28, 2021
For the first time ever, we are releasing an active recommendation to the general public as three-time recommendation Dicerna Pharmaceuticals was acquired by Novo Nordisk in a $3.3 billion deal.
By Maxx Chatsko
Premium Advisor Update
Can Better Antibodies Disrupt Cell Therapy?
Dec 20, 2021
By Maxx Chatsko
Video
Maxx’s Top Stock for December 2021
Dec 1, 2021
7investing Lead Advisor Maxx Chatsko's top stock to buy in December 2021 has just de-risked the entire therapeutic modality of gene therapy -- and Wall Street is entirely misunderstanding the...
By Maxx Chatsko
Video
Maxx’s Top Stock for November 2021
Nov 1, 2021
7investing Lead Advisor Maxx Chatsko's top stock to buy in November 2021 is at the very beginning of an inflection point in its growth trajectory.
By Maxx Chatsko
Article
Navigating Inflation and Interest Rates with Your Hard-Earned Money
Oct 22, 2021
Even long-term investors should acknowledge the role that Fed policy is playing in stock valuations.
By Maxx Chatsko
Premium Advisor Update
Supplement Your Approach to Health and Investing with A Dose…
Oct 14, 2021
Biotechnology
Premium Advisor Update
Drug Development is Risky. Let’s Count the Ways.
Oct 14, 2021
By Maxx Chatsko
Article
Can Your Gene Editing Stocks Survive the End of Momentum?
Oct 8, 2021
There are both opportunities and challenges to modifying DNA for therapeutic applications, but objective information is scarce.
By Maxx Chatsko
Article
Why are $100 Billion Drug Developers Such Lousy Investments?
Sep 23, 2021
While 18 companies have crossed that valuation milestone, only one has consistently outperformed the S&P 500 after.
By Maxx Chatsko
Article
Give Your Thesis Time to Breathe, But Be Objective
Sep 22, 2021
Knowing when to sell an early-stage drug developer isn't easy, but it's nearly impossible when you're a cheerleader.
By Maxx Chatsko
Article
What’s Next for mRNA?
Sep 15, 2021
The therapeutic modality is well-suited to create vaccines for infectious diseases. What about other therapeutic areas?
By Maxx Chatsko
Premium Advisor Update
Swimming With Sharks When There’s Blood in the Water
Sep 15, 2021
Biotechnology
Premium Advisor Update
Annual 2021 Review: Maxx’s 7investing Recommendations
Sep 14, 2021
By Maxx Chatsko
Article
Repligen Always Seems to Make the Right Moves
Aug 21, 2021
The bioprocess leader quietly keeps delivering for shareholders.
By Maxx Chatsko
